Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Accumulated Expenses (2016 - 2018)

Vanda Pharmaceuticals' Other Accumulated Expenses history spans 8 years, with the latest figure at $2.0 million for Q1 2018.

  • For Q1 2018, Other Accumulated Expenses rose 8.93% year-over-year to $2.0 million; the TTM value through Mar 2018 reached $2.0 million, up 8.93%, while the annual FY2017 figure was $2.0 million, 75.84% up from the prior year.
  • Other Accumulated Expenses for Q1 2018 was $2.0 million at Vanda Pharmaceuticals, up from $2.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.0 million in Q1 2018 and bottomed at $614000.0 in Q1 2014.
  • The 5-year median for Other Accumulated Expenses is $1.6 million (2015), against an average of $1.5 million.
  • The largest annual shift saw Other Accumulated Expenses surged 4555.56% in 2014 before it plummeted 32.66% in 2016.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.0 million in 2014, then dropped by 16.63% to $1.7 million in 2015, then tumbled by 32.66% to $1.1 million in 2016, then soared by 75.84% to $2.0 million in 2017, then rose by 1.5% to $2.0 million in 2018.
  • Per Business Quant, the three most recent readings for VNDA's Other Accumulated Expenses are $2.0 million (Q1 2018), $2.0 million (Q4 2017), and $1.9 million (Q3 2017).